PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Recognizes ChromaDex for the Unique Potential its Commercially Available Product Offers in the Human Nutrition Industry - Frost & Sullivan recognizes ChromaDex, Inc. (ChromaDex) with the 2010 North American Frost & Sullivan Award for Most Promising Ingredient of the Year for the unique ingredient it offers under the brand name pTeroPure™ pterostilbene
Frost & Sullivan Recognizes ChromaDex for the Unique Potential its Commercially Available Product Offers in the Human Nutrition Industry

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2011/04/28 - Frost & Sullivan recognizes ChromaDex, Inc. (ChromaDex) with the 2010 North American Frost & Sullivan Award for Most Promising Ingredient of the Year for the unique ingredient it offers under the brand name pTeroPure™ pterostilbene.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the health ingredients market, Frost & Sullivan recognizes ChromaDex, Inc. (ChromaDex) with the 2010 North American Frost & Sullivan Award for Most Promising Ingredient of the Year for the unique ingredient it offers under the brand name pTeroPure™ pterostilbene, a 99% pure form of trans-pterostilbene – a compound found in small berries, other small fruits and in the bark and heartwood of some trees. It is a phytoalexin produced by plants to fight infections from bacteria or fungi and has shown promising health benefits while gaining rapid traction in the nutraceutical industry.

ChromaDex uses a patent-pending, sustainable process and green chemistry to produce pTeroPure pterostilbene in a dose of pterostilbene equivalent to that contained in over 300 pounds of blueberries. "ChromaDex's sustainable process provides a commercially viable manufacturing source, setting the foundation for the company to serve a multitude of markets beyond just the nutraceutical industry," remarks Frost & Sullivan analyst Sneha Pasricha.

Pterostilbene has similar properties to resveratrol, a compound credited for giving red wine its healthy properties. However, it has higher potential for cellular uptake due to its lipophilic nature and longer half-life in the body (105 minutes versus resveratrol"s 15 minutes). These highly beneficial properties are expected to guarantee huge market potential for pterostilbene in the human nutrition industry.

One of the key factors that provide a marketing edge to pterostilbene is the concerted research initiatives undertaken by ChromaDex in collaboration with pertinent research institutions. The company's studies, along with those of the USDA and University of Mississippi, show that pterostilbene may positively impact clinical conditions such as cardiovascular diseases and cognitive decline. Studies have also indicated positive outcomes for diabetes, blood pressure, cancer, oxidative stress and anti-ageing.

Prior to the formal launch of pTeroPure pterostilbene in September 2010, ChromaDex carried out a soft launch of the product in April 2010. Between April and September 2010, the ingredient was incorporated in three finished products in the nutraceutical industry. However, after the formal launch (between September and December 2010), it was employed in 11 more finished products with an additional 12 set to launch by the summer of 2011. Such a positive market acceptance is a strong evidence of the ingredient's growth potential.

"In addition to the persistent research endeavors, ChromaDex adopts a combination of strategies that ensures a promising growth potential for the branded multi-functional ingredient," notes Pasricha. "The company is not only planning to expand the application potential of the compound beyond nutraceuticals, but is gathering patents to strengthen the Intellectual Property body for pterostilbene. It is using smart market positioning and distribution strategies and also is looking to foray to other geographical markets outside the United States."

The marketing and promotional activities for pTeroPure pterostilbene are primarily targeted at end-product manufacturing companies. ChromaDex actively advertises its multi-beneficial health ingredient in trade publications, regularly participates in trade shows, seminars and exhibitions, organizes webinars and uses monthly mails to make its clients aware of special pricing/promotions and to provide new marketing material.

As more pTeroPure pterostilbene-containing end-products are made available in the market, this campaign is expected to help enhance consumer awareness of pterostilbene and the products containing it. Co-branding on finished products is another key marketing tool pursued aggressively by ChromaDex.

"An ingredient with proven efficacy and safety that addresses the needs of multi-populations is bound to be successful," concludes Pasricha. "Moreover, a sustainable production process and apt promotional, market positioning and penetration initiatives are likely to further bolster the ingredient"s potential and future market acceptance."

ChromaDex has exhibited the necessary best practices and growth strategies needed to drive the uptake of its promising pTeroPure in the health ingredient market. Based on the growth potential the compound holds, Frost & Sullivan is proud to present it with the 2010 Frost & Sullivan Most Promising Ingredient of the Year Award. The award recognizes the unique selling features of the product evident in its current market acceptance along with its immense growth potential. It also recognizes the company"s continuous research efforts and marketing and promotional endeavors.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About ChromaDex
ChromaDexTM is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB)

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO"s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Recognizes ChromaDex for the Unique Potential its Commercially Available Product Offers in the Human Nutrition Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan | ChromaDex Newsroom
Publisher Contact: Mireya Espinoza 
210-247-3870 mireya.espinoza[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)